title: [Dysmetabolic syndrome related to HIV-1 protease inhibitors. Review of the literature and personal data].
abstract: HIV-positive patients receiving antiretroviral therapy with HIV-1 protease-inhibitors (PI) frequently show insulin-resistance, impaired glucose tolerance, hypertriglyceridaemia and lipodystrophy (LD). LD has often been reported only after the beginning of PI therapy. Some authors link LD to HIV chronic infection, some others suggest that PIs increase pre-existent disturb. Preliminary data of an observational study drawn in IV day-hospital of Spallanzani Institute in Rome showed hypertriglyceridaemia in 36.4% and hyperglycaemia in 11.2% of patients treated with PI. Carr suggests that such drugs should have this lipid-increasing effect because of their inhibition of low density lipoprotein-receptor-related protein, cytoplasmic retinoic-acid binding protein type 1 and P450 3A cytochrome. This theory doesn't explain why both untreated patients and treated with only reverse transcriptase inhibitors show sometimes the same disorders. According to another hypothesis Tumor necrosis factor-alpha, through inhibition of lipoprotein-lipase, would determine high fat-storage in the adipose tissue. Cardiovascular risk factors have always to be assessed before starting a therapy with PI. Glycaemia, triglyceridaemia, cholesterolaemia have to be performed every three months during the treatment and, if necessary, C-Peptide and insulinaemia too. A treatment with lipid-lowering drugs is always recommended in patients with hypertriglyceridaemia > 500 mg/dl and/or hypercholesterolaemia LDL > 190 mg/dl in two following checks. Fibrates have proven to be effective in reducing hypertriglyceridaemia, but there is no certainty that such therapies could have good effects on the LD itself too.
authors.affiliation: IV Divisione Malattie Infettive, IRCCS Lazzaro Spallanzani, Roma. ursor@tin.it
authors.forename: R
authors.initials: R
authors.lastname: Urso
authors.forename: G F
authors.initials: GF
authors.lastname: Croce
authors.forename: C
authors.initials: C
authors.lastname: Tubili
authors.forename: M
authors.initials: M
authors.lastname: De Marco
authors.forename: P
authors.initials: P
authors.lastname: La Scala
authors.forename: D
authors.initials: D
authors.lastname: Luglio
authors.forename: P
authors.initials: P
authors.lastname: Narciso
mesh_terms: D048909:Diabetes Complications; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D015497:HIV-1 / Q000201:enzymology*; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced* / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007049:Iatrogenic Disease; D007333:Insulin Resistance; D008060:Lipodystrophy / Q000139:chemically induced*; D008297:Male; D012307:Risk Factors
chemical_list: D017320:HIV Protease Inhibitors; D000960:Hypolipidemic Agents